# 23andMe

Type: Company (ME)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/23andme
Canonical HTML page: https://getbiobrief.com/entity/23andme

## Recent coverage (3 stories)

### 23andMe's $46.75M data breach toll and the genetic testing trust deficit
2026-07-25 08:04:22 · Sentiment: Negative · Impact: 7/10 · Sources: 3

23andMe's $46.75 million settlement for the 6.9 million customer data leak highlights the fragility of consumer genetic testing demand. Already in bankruptcy from declining interest, the breach reinforces trust erosion in direct-to-consumer genomics, prompting shifts in industry data stewardship standards.
Full story: https://getbiobrief.com/story/23andme-breach-bio-trust-deficit

### 23andMe's $18M Breach Penalty: A Wake-Up Call for Biotech's Genomic Goldmine
2026-07-19 23:47:35 · Sentiment: Negative · Impact: 7/10 · Sources: 7

The $18 million settlement over 6.9 million exposed genetic profiles sends a shockwave through the biotech sector. It underscores how consumer genomics data—once a research treasure trove—can become a career-ending liability when security fails.
Full story: https://getbiobrief.com/story/23andme-18m-settlement-biotech-genomic-data

### Post-Acquisition Blow: 23andMe Buyer Hit with $47M Genetic Data Breach Fine
2026-07-08 01:15:06 · Sentiment: Negative · Impact: 7/10 · Sources: 1

For the biotech world, the 23andMe saga is a stark lesson: acquiring assets out of bankruptcy does not shield from inherited data-breach liabilities. Anne Wojcicki’s $305 million purchase now carries a $46.75 million settlement that could chill future investments in consumer genomics.
Full story: https://getbiobrief.com/story/23andme-acquisition-breach-liability-biotech-valuation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.